Relmada Therapeutics (RLMD) Research & Development (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Research & Development data on file, last reported at $8.1 million in Q1 2026.

• Research & Development for Q1 2026 came in at $8.1 million, down 32.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $23.0 million (down 48.65% YoY), and the FY2025 annual result was $26.9 million, down 41.79% from the prior year.
• Research & Development was little changed at $8.1 million in Q1 2026 per RLMD's latest filing, from $8.1 million in the prior quarter.
• Over five years, Research & Development peaked at $30.9 million in Q2 2022 and troughed at $2.8 million in Q2 2025.
• A 5-year average of $14.7 million and a median of $12.0 million in 2025 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2025: Research & Development jumped 78.38% in 2022, then sank 73.7% in 2025.
• A 5-year view of Research & Development shows it stood at $26.9 million in 2022, then sank by 45.1% to $14.8 million in 2023, then slipped by 25.43% to $11.0 million in 2024, then declined by 26.61% to $8.1 million in 2025, then gained by 0.19% to $8.1 million in 2026.
• Business Quant data shows RLMD's Research & Development at $8.1 million in Q1 2026, $8.1 million in Q4 2025, and $4.0 million in Q3 2025.